How heparins can interfere with argatroban blood tests
Official title: HEPARINS: INTERFERENCE IN ARGATROBAN MEASUREMENT
Run by University Hospital, Strasbourg, France · NCT07302620 · Data updated 2026-11-12
This project will test whether remaining heparin in blood samples changes laboratory measurements of argatroban activity for adults treated with UFH or LMWH.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 70 (estimated) |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Status | Recruiting |
| Started | December 3, 2024 |
| Main results expected | January 2026 |
| Study ends | January 2026 |
| Registry record updated | December 24, 2025 |
| Trial ID | NCT07302620 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) who are anticoagulated with unfractionated heparin or low molecular weight heparin and whose samples are sent to the Hematology Laboratory of Strasbourg for anti-Xa testing.
✕Probably not a fit
Patients receiving anticoagulants other than UFH or LMWH, pediatric patients, or those whose samples are not analyzed at the Strasbourg HUS laboratory are unlikely to benefit directly from this work.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational analysis of routine blood samples sent to the Hematology Laboratory of the University Hospitals of Strasbourg from adults anticoagulated with unfractionated heparin or low molecular weight heparins. The laboratory currently uses a modified thrombin time calibrated for argatroban alongside anti-Xa measurements, and the study will examine how prior heparin exposure affects measured anti-IIa activity. By comparing assay results from samples with known heparin exposures, the team will quantify any overestimation of argatroban activity. Results aim to improve interpretation of argatroban monitoring when patients are switched from heparin products.
Why it matters
Potential benefit: If successful, the findings could help laboratories measure argatroban more accurately and reduce bleeding or clotting risks when patients switch from heparin.
How similar studies have gone: Prior reports have described heparin interference with argatroban assays, but comprehensive, real-world laboratory evaluations of this interference are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criterias: * Adult patient (≥ 18 years) * Patient anticoagulated with UFH or LMWH * Sample sent to the Hematology Laboratory of the University Hospitals of Strasbourg (HUS) and analyzed for measurement of the anti-Xa activity of an anticoagulant in routine care Exclusion Criteria: * Patient receiving an anticoagulant other than UFH or LMWH * Insufficient sample volume
Where it's running
-
Laboratoire d'Hématologie - Unité d'Hémostase - CHU de Strasbourg - France
Strasbourg, France Recruiting
Study contacts
- Study coordinator: Agathe HERB, PharmD
- Email: agathe.herb@chru-strasbourg.fr
- Phone: 33 3 88 12 75 53
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating flow-diverting stents for treating cerebral aneurysms
This study is testing two types of stents to see if they can safely and effectively treat cerebral aneurysms in patients across several hospitals in Spain.
-
Investigating Clonal Hematopoiesis and Neutrophil Extracellular Traps in Venous Thrombosis
This study is trying to see if certain blood changes are linked to repeated blood clots in younger people who don’t have the usual risk factors.
-
Remote care for people with low-risk blood clots (DVT or PE)
This study will test whether giving people with low-risk deep vein thrombosis or pulmonary embolism a 4G tablet and remote follow-up improves coordination of care and treatment adherence over 6 months and 1 year.
-
Evaluating endovascular treatment for blood clots in the legs
This study is testing new treatments for blood clots in the legs to see if they are safe and effective for patients with certain types of blockages.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.